Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Calcium signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
2 Calcium signaling pathway 💬
6件: FLT1, FLT4, KDR, PDGFRA, PDGFRB, RET 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
3 Calcium signaling pathway 💬
4件: FLT4, KDR, PDGFRB, RET 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
4 Calcium signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
5 Calcium signaling pathway 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
6 Calcium signaling pathway 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
7 Central carbon metabolism in cancer 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
8 Central carbon metabolism in cancer 💬
5件: FLT3, KIT, PDGFRA, PDGFRB, RET 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
9 Central carbon metabolism in cancer 💬
5件: FLT3, KIT, PDGFRB, RAF1, RET 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
10 Central carbon metabolism in cancer 💬
3件: KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
11 Central carbon metabolism in cancer 💬
2件: KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
12 Central carbon metabolism in cancer 💬
2件: KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
13 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
14 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
15 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
16 Choline metabolism in cancer 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
17 Choline metabolism in cancer 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
18 Choline metabolism in cancer 💬
2件: PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
19 EGFR tyrosine kinase inhibitor resistance 💬
4件: BRAF, KDR, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
20 EGFR tyrosine kinase inhibitor resistance 💬
5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
21 EGFR tyrosine kinase inhibitor resistance 💬
3件: KDR, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
22 EGFR tyrosine kinase inhibitor resistance 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
23 EGFR tyrosine kinase inhibitor resistance 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
24 EGFR tyrosine kinase inhibitor resistance 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
25 Focal adhesion 💬
5件: BRAF, FLT4, KDR, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
26 Focal adhesion 💬
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
27 Focal adhesion 💬
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
28 Focal adhesion 💬
3件: FYN, PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
29 Focal adhesion 💬
3件: FYN, PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
30 Focal adhesion 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
31 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
32 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
33 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
34 Gap junction 💬
2件: PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
35 Gap junction 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
36 Gap junction 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
37 Glioma 💬
3件: BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
38 Glioma 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
39 Glioma 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
40 Glioma 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
41 Glioma 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
42 Glioma 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
43 Human papillomavirus infection 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
44 Human papillomavirus infection 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
45 Human papillomavirus infection 💬
1件: PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
46 Human papillomavirus infection 💬
1件: PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
47 Human papillomavirus infection 💬
1件: PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
48 Human papillomavirus infection 💬
2件: PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
49 JAK-STAT signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
50 JAK-STAT signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
51 JAK-STAT signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
52 JAK-STAT signaling pathway 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
53 JAK-STAT signaling pathway 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
54 JAK-STAT signaling pathway 💬
2件: PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
55 MAPK signaling pathway 💬
7件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
56 MAPK signaling pathway 💬
8件: CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
57 MAPK signaling pathway 💬
3件: EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
58 MAPK signaling pathway 💬
3件: EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
59 MAPK signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
60 MAPK signaling pathway 💬
3件: KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
61 Melanoma 💬
3件: BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
62 Melanoma 💬
3件: FGFR1, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
63 Melanoma 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
64 Melanoma 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
65 Melanoma 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
66 Melanoma 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
67 MicroRNAs in cancer 💬
3件: ABL1, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
68 MicroRNAs in cancer 💬
2件: ABL1, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
69 MicroRNAs in cancer 💬
2件: ABL1, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
70 MicroRNAs in cancer 💬
3件: FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
71 MicroRNAs in cancer 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
72 MicroRNAs in cancer 💬
2件: PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
73 Pathways in cancer 💬
4件: ABL1, KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
74 Pathways in cancer 💬
3件: ABL1, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
75 Pathways in cancer 💬
3件: ABL1, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
76 Pathways in cancer 💬
7件: BRAF, FLT3, FLT4, KIT, PDGFRB, RAF1, RET 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
77 Pathways in cancer 💬
7件: CSF1R, FLT3, FLT4, KIT, PDGFRA, PDGFRB, RET 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
78 Pathways in cancer 💬
6件: FGFR1, FGFR2, FGFR3, FLT4, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
79 Phospholipase D signaling pathway 💬
3件: FYN, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
80 Phospholipase D signaling pathway 💬
3件: FYN, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
81 Phospholipase D signaling pathway 💬
3件: KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
82 Phospholipase D signaling pathway 💬
3件: KIT, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
83 Phospholipase D signaling pathway 💬
3件: KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
84 Phospholipase D signaling pathway 💬
2件: PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
85 PI3K-Akt signaling pathway 💬
8件: CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
86 PI3K-Akt signaling pathway 💬
3件: EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
87 PI3K-Akt signaling pathway 💬
3件: EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
88 PI3K-Akt signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
89 PI3K-Akt signaling pathway 💬
6件: FLT3, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
90 PI3K-Akt signaling pathway 💬
3件: KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
91 Prostate cancer 💬
3件: BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
92 Prostate cancer 💬
4件: FGFR1, FGFR2, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
93 Prostate cancer 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
94 Prostate cancer 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
95 Prostate cancer 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
96 Prostate cancer 💬
1件: PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
97 Rap1 signaling pathway 💬
6件: BRAF, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
98 Rap1 signaling pathway 💬
7件: CSF1R, FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
99 Rap1 signaling pathway 💬
4件: EPHA2, KIT, PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
100 Rap1 signaling pathway 💬
4件: EPHA2, KIT, PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
101 Rap1 signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
102 Rap1 signaling pathway 💬
3件: KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
103 Ras signaling pathway 💬
4件: ABL1, EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
104 Ras signaling pathway 💬
4件: ABL1, EPHA2, KIT, PDGFRB 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
105 Ras signaling pathway 💬
4件: ABL1, KIT, PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
106 Ras signaling pathway 💬
8件: CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
107 Ras signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
108 Ras signaling pathway 💬
6件: FLT3, FLT4, KDR, KIT, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
109 Regulation of actin cytoskeleton 💬
3件: BRAF, PDGFRB, RAF1 💬 Sorafenib 💬 Sorafenib 2件: 34, 86 💬
110 Regulation of actin cytoskeleton 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 Nintedanib 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
111 Regulation of actin cytoskeleton 💬
2件: PDGFRA, PDGFRB 💬 Nilotinib 💬 Nilotinib 5件:  6 ,  8 , 34, 51, 86 💬
112 Regulation of actin cytoskeleton 💬
2件: PDGFRA, PDGFRB 💬 Sunitinib 💬 Sunitinib 2件: 28, 34 💬
113 Regulation of actin cytoskeleton 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬
114 Regulation of actin cytoskeleton 💬
2件: PDGFRB, SRC 💬 Dasatinib 💬 Dasatinib 2件: 51, 85 💬